Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury
Open Access
- 1 November 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 19 (11), 2086-2097
- https://doi.org/10.1681/asn.2007070794
Abstract
The Rho kinase pathway plays an important role in dedifferentiation of epithelial cells and infiltration of inflammatory cells. For testing of the hypothesis that blockade of this cascade within the kidneys might be beneficial in the treatment of renal injury the Rho kinase inhibitor, Y27632 was coupled to lysozyme, a low molecular weight protein that is filtered through the glomerulus and is reabsorbed in proximal tubular cells. Pharmacokinetic studies with Y27632-lysozyme confirmed that the conjugate rapidly and extensively accumulated in the kidney. Treatment with Y27632-lysozyme substantially inhibited ischemia/reperfusion-induced tubular damage, indicated by reduced staining of the dedifferentiation markers kidney injury molecule 1 and vimentin, and increased E-cadherin relative to controls. Rho kinase activation was inhibited by Y27632-lysozyme within tubular cells and the interstitium. Y27632-lysozyme also inhibited inflammation and fibrogenesis, indicated by a reduction in gene expression of monocyte chemoattractant protein 1, procollagen Iα1, TGF-β1, tissue inhibitor of metalloproteinase 1, and α-smooth muscle actin. Immunohistochemistry revealed reduced macrophage infiltration and decreased expression of α-smooth muscle actin, collagen I, collagen III, and fibronectin. In contrast, unconjugated Y27632 did not have these beneficial effects but instead caused systemic adverse effects, such as leukopenia. Neither treatment improved renal function in the bilateral ischemia/reperfusion model. In conclusion, the renally targeted Y27632-lysozyme conjugate strongly inhibits tubular damage, inflammation, and fibrogenesis induced by ischemia/reperfusion injury.Keywords
This publication has 46 references indexed in Scilit:
- Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidneyAmerican Journal of Physiology-Renal Physiology, 2006
- TGFβ1 induces epithelial–mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary cultureInternational Journal of Experimental Pathology, 2006
- Tubuloglomerular feedback-dependent modulation of renal myogenic autoregulation by nitric oxideAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2006
- Defective RhoA/Rho-Kinase Signaling Contributes to Vascular Hypocontractility and Vasodilation in Cirrhotic RatsGastroenterology, 2006
- Mechanisms of Disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietinNature Clinical Practice Nephrology, 2005
- The Rho-kinase pathway regulates angiotensin II-induced renal damageKidney International, 2005
- RhoGTPase Activation Is a Key Step in Renal Epithelial Mesenchymal TransdifferentiationJournal of the American Society of Nephrology, 2005
- Ischemic acute renal failure: An inflammatory disease?Kidney International, 2004
- Vessel- and Vasoconstrictor-Dependent Role of Rho/Rho-Kinase in Renal Microvascular ToneJournal of Vascular Research, 2003
- Hospital-acquired renal insufficiencyAmerican Journal of Kidney Diseases, 2002